What question did this study set out to answer?

June 20, 2026Open Access

Prevalence, Predictors, and Management of Anemia in Chronic Kidney Disease – A Retrospective Longitudinal Analysis of Treatment Outcomes

Key Points

The study aimed to assess the prevalence, predictors, and management strategies of anemia in patients with chronic kidney disease.
Conducted a retrospective longitudinal study among 300 patients with chronic kidney disease.
Collected data on anemia prevalence, socio-demographic factors, treatment strategies, and renal outcomes.
Analyzed predictors of anemia using multivariable logistic regression and assessed treatment effectiveness after three months.
Anemia prevalence was 80.0% among patients with CKD, significantly higher in males (94.3%) than females (72.3%), p < 0.001.
Males had higher odds of anemia (AOR: 5.07, 95% CI: 1.81-14.23, p = 0.002).
Hematological improvements were noted with a rise of 1.32 g/dL in hemoglobin and 4.05% in packed cell volume.

Abstract

Background: Anemia is a common and serious complication of chronic kidney disease (CKD), contributing to increased morbidity, reduced quality of life, and accelerated disease progression. Its prevalence varies globally, influenced by factors such as healthcare access, socioeconomic conditions, and disease management strategies. Objectives: This study assessed the prevalence, predictors, and management strategies of anemia along with treatment outcomes over three months among patients with CKD. Material and Methods: A retrospective longitudinal study was conducted among 300 patients with CKD. Data on anemia prevalence, socio-demographic factors, treatment strategies, and hematologic, and renal outcomes were collected and analyzed. Multivariable logistic regression was used to identify predictors of anemia. Treatment effectiveness was assessed based on changes in hematological parameters (hemoglobin Hb and packed cell volume PCV), creatinine, and glomerular filtration rate after three months. The probability value for statistical significance was set at <0.05. Results: Anemia was observed in 80.0% of patients with CKD. Anemia was significantly more common in males (94.3%) than females (72.3%) ( p < 0.001) and was more prevalent among employed individuals (88.9%) compared to the unemployed (75.0%) ( p = 0.007). Males had significantly higher odds of anemia (AOR: 5.07, 95% CI: 1.81-14.23, p = 0.002). Pharmacological treatment alone was the most common approach (81.1%), followed by combined pharmacologic and blood transfusion therapy (14.2%) and transfusion alone (4.7%). The most frequently used drugs were folic acid (47.1%) and iron supplements (44.6%). Among 99 patients with post-treatment data, Hb and PCV significantly improved by 1.32 g/dL and 4.05%, respectively. Conclusion: In this study, anemia is highly prevalent among patients with CKD, with the male sex as a significant predictor. Pharmacological therapy was the mainstay of treatment, yielding significant improvements in hematologic parameters. However, further interventions may be needed to optimize renal function outcomes. Policies promoting early detection and treatment of anemia in CKD are crucial for improving patient outcomes.

Bookmark

View Full Paper